Literature DB >> 35913522

Recognition of functional genetic polymorphism using ESE motif definition: a conservative evolutionary approach to CYP2D6/CYP2C19 gene variants.

Mitra Samadi1, Laleh Beigi1, Fatemeh Yadegari1, Alireza Madjid Ansari1, Keivan Majidzadeh-A1, Maryam Eskordi1, Leila Farahmand2.   

Abstract

Although predicting the effects of variants near intron-exon boundaries is relatively straightforward, predicting the functional Exon Splicing Enhancers (ESEs) and the possible effects of variants within ESEs remains a challenge. Considering the essential role of CYP2D6/CYP2C19 genes in drug metabolism, we attempted to identify variants that are most likely to disrupt splicing through their effect on these ESEs. ESEs were predicted in these two genes using ESEfinder 3.0, incorporating a series of filters (increased threshold and evolutionary conservation). Finally, reported mutations were evaluated for their potential to disrupt splicing by affecting these ESEs. Initially, 169 and 243 ESEs were predicted for CYP2C19/CYP2D6, respectively. However, applying the filters, the number of predicted ESEs was reduced to 26 and 19 in CYP2C19/CYP2D6, respectively. Comparing prioritized predicted ESEs with known sequence variants in CYP2C19/CYP2D6 genes highlights 18 variations within conserved ESEs for each gene. We found good agreement in cases where such predictions could be compared to experimental evidence. In total, we prioritized a subset of mutational changes in CYP2C19/CYP2D6 genes that may affect the function of these genes and lead to altered drug responses. Clinical studies and functional analysis for investigating detailed functional consequences of the mentioned mutations and their phenotypic outcomes is mostly recommended.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  CYP2C19; CYP2D6; ESEfinder; Exonic splicing enhancers; Variations

Year:  2022        PMID: 35913522     DOI: 10.1007/s10709-022-00161-x

Source DB:  PubMed          Journal:  Genetica        ISSN: 0016-6707            Impact factor:   1.633


  37 in total

Review 1.  Exonic splicing enhancers: mechanism of action, diversity and role in human genetic diseases.

Authors:  B J Blencowe
Journal:  Trends Biochem Sci       Date:  2000-03       Impact factor: 13.807

Review 2.  Mechanisms of alternative pre-messenger RNA splicing.

Authors:  Douglas L Black
Journal:  Annu Rev Biochem       Date:  2003-02-27       Impact factor: 23.643

3.  BRCA2 T2722R is a deleterious allele that causes exon skipping.

Authors:  James D Fackenthal; Luca Cartegni; Adrian R Krainer; Olufunmilayo I Olopade
Journal:  Am J Hum Genet       Date:  2002-07-19       Impact factor: 11.025

4.  RESCUE-ESE identifies candidate exonic splicing enhancers in vertebrate exons.

Authors:  William G Fairbrother; Gene W Yeo; Rufang Yeh; Paul Goldstein; Matthew Mawson; Phillip A Sharp; Christopher B Burge
Journal:  Nucleic Acids Res       Date:  2004-07-01       Impact factor: 16.971

5.  In vitro functional analysis of 24 novel CYP2C19 variants recently found in the Chinese Han population.

Authors:  Da-Peng Dai; Li-Ming Hu; Pei-Wu Geng; Shuang-Hu Wang; Jie Cai; Guo-Xin Hu; Jian-Ping Cai
Journal:  Xenobiotica       Date:  2015-07-07       Impact factor: 1.908

6.  Characterization of Cyp2d22, a novel cytochrome P450 expressed in mouse mammary cells.

Authors:  N Blume; J Leonard; Z J Xu; O Watanabe; H Remotti; J Fishman
Journal:  Arch Biochem Biophys       Date:  2000-09-15       Impact factor: 4.013

7.  Analysis of the RNA-recognition motif and RS and RGG domains: conservation in metazoan pre-mRNA splicing factors.

Authors:  E Birney; S Kumar; A R Krainer
Journal:  Nucleic Acids Res       Date:  1993-12-25       Impact factor: 16.971

8.  ESEfinder: A web resource to identify exonic splicing enhancers.

Authors:  Luca Cartegni; Jinhua Wang; Zhengwei Zhu; Michael Q Zhang; Adrian R Krainer
Journal:  Nucleic Acids Res       Date:  2003-07-01       Impact factor: 16.971

Review 9.  Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.

Authors:  K R Crews; A Gaedigk; H M Dunnenberger; J S Leeder; T E Klein; K E Caudle; C E Haidar; D D Shen; J T Callaghan; S Sadhasivam; C A Prows; E D Kharasch; T C Skaar
Journal:  Clin Pharmacol Ther       Date:  2014-01-23       Impact factor: 6.875

10.  Functional characterization of a first avian cytochrome P450 of the CYP2D subfamily (CYP2D49).

Authors:  Hua Cai; Jun Jiang; Qi Yang; Qingmei Chen; Yiqun Deng
Journal:  PLoS One       Date:  2012-06-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.